GlassScriptPhysician profile
Howard Saiontz
NPI 1295738334
$4,283.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $3,780 · 2021: $215.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $3,600.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $108.60 | 2019 | |
| Incyte Corporation | $97.07 | 2021 | |
| Seagen INC. | $79.99 | 2021 | |
| Dova Pharmaceuticals | $72.15 | 2020 | |
| Astellas Pharma US INC | $64.99 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.87 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $38.55 | 2019-2021 | |
| Kite Pharma, INC. | $27.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.78 | 2019 | |
| Karyopharm Therapeutics INC. | $23.81 | 2020 | |
| Exelixis INC. | $22.36 | 2019 | |
| Janssen Biotech, INC. | $20.79 | 2021 | |
| Amgen INC. | $19.08 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Saiontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.